Suraksha Diagnostic Limited has informed the Exchange about Transcript
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported FY26 revenue of INR 3,104 million, up 23.1% YoY with a 3-year CAGR of 17.78%. EBITDA stood at INR 985 million (31.73% margin), with PAT at INR 314 million (10.1% margin). The company served 1.37 million patients across 8.16 million tests. Mature centers generate 36-37% EBITDA margins while new centers (under 2 years) are loss-making at -5.5%. The company operates 68 centers and plans to add 3 hubs and 8 spokes in FY27, expanding to Bihar, Tripura, and Jharkhand with INR 70 crore capex. Guwahati in Assam is showing the best traction outside West Bengal. Genomics vertical is generating INR 35 lakhs per month run rate.
Management guided for FY27 revenue growth of around 15% with EBITDA margins recovering to 33% as new centers ramp up. Medium-term margin target is 35%, with long-term potential of 38-39% as expansion normalizes. The gap between mature and blended margins represents future profitability runway as newer centers scale.